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sions were significantly lower for arformoterol patients than Neb-SABA patients
(8.7% vs. 12.1%, p0.0169). Adjusted odds of readmission were estimated to be 44%
less for arformoterol patients (OR 0.56, 95% CI 0.41-0.78). CONCLUSIONS: All-cause
30-day readmissions were significantly fewer for arformoterol patients than neb-
SABA patients, both before and after adjusting for patient and hospital factors such
as ICU care.
RESPIRATORY-RELATED DISORDERS – Research on Methods
PRS50
IS IT APPROPRIATE TO MEASURE ASTHMA CONTROLLER ADHERENCE USING
PHARMACY CLAIMS DATA?
Visaria J, Frazee SG, Henderson RR
Express Scripts, Inc., St. Louis, MO, USA
While possession-based adherence measures are typically used to compare med-
ication adherence using pharmacy claims, thesemeasures are difficult to verify for
inhaled asthma medications because the claim-reported days’ supply may not
reflect the actual duration of use. OBJECTIVES: To compare medication adherence
to all asthma controllers to that in subsets of patients using Flucitasone/Salmeterol
disk with inhalation device (combination inhaler, CI) or leukotriene inhibitors (LT)
which are more likely to accurately reflect days’ supply in the claim, across phar-
macy dispensing channels. METHODS: Commercially insured US patients aged
12-63 and medically diagnosed for asthma were followed for one year after initia-
tion of an asthma controller using a retrospective, claims-based design. Adherence
was defined using Medication Possession Ratio (MPR). CI and LT subsets included
all patients using one of these as the indexmedications. Themultivariate-adjusted
relationship between adherence and channel was evaluated using a generalized
linear model. RESULTS: A total of 6014 patients were included in the overall study
cohort, with 2222 in theCI subgroup and 1884 in the LT subgroup. The adjustedMPR
for asthma controllers in the retail pharmacy cohort was 39.70% (95% CI 37.08-
42.52%) compared to 62.43 (95% CI 58.19-66.97%) in the mail-order cohort. In com-
parison, the adjusted MPR for retail andmail-order pharmacy cohorts were 38.33%
(95% CI 34.58 - 42.49%) and 57.85 (95% CI 52.13-64.20%) in the CI subgroup and
49.01% (95% CI 43.83-54.79%) and 69.25 (95% CI 52.13-77.56%) in the LT subgroup,
respectively. CONCLUSIONS: In a large, nationally representative cohort, adher-
ence to asthma controllers and differences in adherence across dispensing chan-
nels were similar inmagnitude to those in two subgroups withmore accurate days
supply information. It may be reasonable to use possession-based asthma adher-
ence measures derived from pharmacy claims, despite potential errors in captur-
ing days’ supply.
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COMPARISON OF RISK ADJUSTMENT MODELS IN PREDICTING DISEASE
SPECIFIC AND TOTAL HEALTH CARE EXPENDITURE FOR COPD
Patel JG, Johnson ML, Aparasu RR
University of Houston, Houston, TX, USA
OBJECTIVES: To compare and determine the best risk adjustment model for pre-
dicting disease specific and total health care expenditure associated with Chronic
Obstructive Pulmonary Disease (COPD). METHODS: Data from 2005-2008 Medical
Expenditure Panel Survey, involving adults 18 years with COPD diagnosis were
used to evaluate risk adjustment measures. The outcomes of COPD specific health
care expenditure, total inpatient expenditure, total outpatient expenditure and
total health care expenditure weremodeled using linear regression. Baseline char-
acteristics included age, gender and race. The six different risk adjustment mea-
sures compared were total number of medications, total number of respiratory
medications, D’Hoore-Charlson, Deyo-Charlson, modified Elixhauser and General
Health Status (GHS). Different combinations of thesemeasures were used to derive
the best risk-adjustment model having the highest Adjusted-R2. Validation of the
risk adjustment measures was performed on 2009 MEPS data. RESULTS: Of the six
risk adjustment measures, the total number of respiratory medications performed
best for predicting COPD specific expenditure (Adj. R2: 24.62%). The total number of
medications best predicted inpatient, outpatient and total health care expendi-
tures (Adj. R2: 17.71%, 6.44% and 32.71% respectively). No combination of risk ad-
justment models led any improvement in predicting COPD specific health care
expenditures. The combination of count of all medications with modified Elix-
hauser index performed best in predicting inpatient, outpatient and total health
care expenditure (Adj.R2: 18.44, 7.91 and 34.87 respectively). CONCLUSIONS:Num-
ber of respiratory medications may be an indicator of severity of the disease,
thereby best predicting the disease specific health care expenditure, where as sim-
ple construct of count of all medications used is the best predictor of total health
care expenditure. Medication-based measures can be effective and easy to use in
risk-adjusting health care expenditures.
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THE STABILITY OF ADDITIVE TREATMENT EFFECTS IN MULTIPLE TREATMENT
COMPARISON META-ANALYSIS: A SIMULATION STUDY
Thorlund K1, Mills E2
1McMaster University, Hamilton, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada
OBJECTIVES:Medical interventions are often administered as treatment combina-
tions (e.g., drug A  drug B). Models for effects of treatment combinations in mul-
tiple treatment comparison meta-analysis (MTCs) have previously been proposed.
The objective of this studywas to evaluate the comparative statistical performance
of the conventional MTC model and an ‘additive effects’ MTC model, in scenarios
where ‘additivity’ holds true (i.e., where the effect of effect of treatment A and B
combined is equal to the sumof the individual effects of treatmentA and treatment
B) and in scenarios where ‘additivity’ is mildly or strongly violated.METHODS:We
simulated MTC scenarios where additivity held true or was violated. We applied
conventional and additive effects Bayesian MTCmodels to the simulated data. We
measured the proportion of over- and underestimated treatment effects, the cov-
erage of the 95% credible intervals, and the statistical power. RESULTS: Under true
additivity, the additive effects model is superior to the conventional model. Under
mildly violated additivity, the additive model is less accurate (more over- and
underestimates), but more precise (comparable coverage and greater power). Un-
der strongly violated additivity, the additive model performs worse in terms of
accuracy and coverage. CONCLUSIONS: The additivemodel may readily be used in
practice when approximate additivity can be assumed.
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TEST-RETEST RELIABILITY OF THE URTICARIA PATIENT DAILY DIARY IN
ELECTRONIC FORMAT AMONG ADULTS AND ADOLESCENTS
Flood E1, Devlen J1, Zazzali J2
1Oxford Outcomes Ltd., an ICON PLC Company, Bethesda, MD, USA, 2Genentech, Inc., South San
Francisco, CA, USA
OBJECTIVES: The Urticaria Patient Daily Diary (UPDD), originally developed in pa-
per format, has beenmigrated to an electronic version. This study was designed to
assess the test-retest reliability of the electronic version (ePRO) of the UPDD.
METHODS: The UPDD includes a morning component, assessing CIU symptoms
and impact on sleep, and an evening component, assessing symptoms, impact on
daily activities, rescue medication use, and contacting a health care provider.
Adults and adolescents with moderate to severe chronic idiopathic urticaria (CIU)
completed the morning and evening ePRO UPDD once, engaged in an hour-long
filler task (Sudoku puzzles), and then completed the UPDD again. Test-retest reli-
ability between the two UPDD completions was assessed by item using a weighted
Kappa, a simple Kappa for a dichotomous item (angioedema), and McNemar’s test
for one item (calling a doctor/nurse). Intraclass correlation coefficients (ICCs) as-
sessed the reliability of the Urticaria Activity Score (UAS), which is the sum of the
‘itch severity’ and ‘number of hives’ item scores. RESULTS: Forty-five patients aged
13 to 74 years (mean 43.6 years) with stable symptoms at time of diary completion
participated. Kappa values ranged from 0.83 to 1.00 for the ePRO UPDD items. The
McNemar’s test yielded a non-significant p-value (p 0.317). For the UAS, ICC was
0.83 for the morning ePRO UPDD and .96 for the evening ePRO UPDD; each of the
Wilcoxon p-values was greater than 0.05. CONCLUSIONS: All Kappas were above
the 0.74 threshold (Coons et al, 2009), indicating excellent test-retest reliability. No
significant differenceswere found between test and retest scores on the UAS or the
‘contacting health care provider’ item. In summary, the ePRO UPDD showed excel-
lent test-retest reliability in a sample of CIU patients whose symptoms were stable
at time of UPDD completion.
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ACCEPTABILITY OF THE SELF-ADMINISTERED COMPUTERIZED (SAC) VERSIONS
OF THE BASELINE/TRANSITION DYSPNEA INDEXES (BDI/TDI) FOR PATIENTS
WITH COPD FROM SEVEN COUNTRIES
Brunel V1, Salmassi L1, White T2, Mahler DA3
1MAPI Institute, Lyon, France, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA,
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OBJECTIVES: The original interviewer-administered versions of the Baseline/Tran-
sition Dyspnea Indexes (BDI/TDI) were modified by the originator to create self-
administered and computerized (SAC) versions. The rationale for the development
of the SAC versions was to offer a standardized method for patients to report the
impact of activities of daily living on the severity of their breathlessness. The
objective of this study is to present the acceptability of the SAC versions of the
BDI/TDI to patients with COPD from seven countries including eight different lan-
guages [Dutch (The Netherlands), English (Canada, UK), Flemish (Belgium), French
(Belgium, Canada), German (Germany), and Spanish (Spain)]. METHODS: A stan-
dardized methodology was followed to translate the SAC BDI/TDI (e.g., forward/
backward step, review by author). The test on 5 COPD patients in each country was
conducted in form of in-depth interviews to evaluate 1) comprehension, and 2)
acceptability using laptop computers. RESULTS: Overall, most patients liked the
SAC versions, and about half preferred it to a interviewer-administered question-
naire. Only four of 35 patients had problems using the mouse to click on the right
answer for the BDI (e.g., difficulties of coordination, or in using the left button). The
items were understood with no difficulties; themain challenging issue was ease in
understanding the equivalents of “Baseline” and “Transition”. At first, 42% of the
patients, especially in Germany (4/5 patients), Spain and UK (3/5 patients), had
difficulties with the instructions to select answers on the TDI using the up-and-
down elevator buttons. These difficulties did not persist after the practice question
designed to help the patients to become familiar with clicking an “X” (BDI), and using
the up-and-down arrows (TDI). CONCLUSIONS: The SAC versions of the BDI/TDI
were well accepted by patients from seven different countries. Special attention
and supervision should be given to patients not familiar with computer use.
PRS55
A NEW CONCEPT OF PATIENT REPORTED OUTCOME ON QUALITY INDICATORS
FOR PHARMACEUTICAL CARE
Huttin C
ENDEPUSresearch and ENDEPResearch Group, Cambridge, MA, USA
OBJECTIVES: A new concept of Patient-Reported Outcome (PRO) on quality indica-
tors for pharmaceutical services is presented. It aims to supplement postmarketing
surveillance tools. It is based on research findings fromapatient survey instrument
designed at Harvard and applied to a Primary Care Group in Warwickshire, as a
quality improvement tool (Value inHealth, vol 5, issue 3, 2002). AHRQ considers the
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indicators for the Clearing House and the measures could complement indicators
on clinical quality of providers from the NIH Promis initiative in the United States
(or the NHS Proms in the UK).METHODS: The concept development is relevant for
chronic care. Five domains represent outpatient drug care: information, commu-
nication access, trust and clinical quality. Four process measures and one access
measure are proposed with series of 5 -7 items, tested on pharmacy delivery sys-
tems and dispensing doctors.The trust indicator has been identified as critical for
the US drug delivery system and discussed as an example. RESULTS: Trust ad-
resses the potential patient mistrust when cost interfere with clinical judgement.
The process measure is calculated for prescribing and treatment decisions for
Hypertension, Diabetes and Asthma.It is a rate base measure . The Facct scoring
method is modified to integrate minima in low score values. Mean scores are cal-
culated on samples per practice. Missing values are replaced by mean value. The
evidence from the UK PCT on a scale of 0-100, for three practices show scores of
66.78; 63.82;73.92 and 67.72 for the whole sample with a Cronbach of 0.70.
CONCLUSIONS:A composite indicator is envisaged for diffferent decision points in
clinical practices. It is to be linked to clinical decision points from the Adaptive
Knowledge Platform (AKP) (Huttin, Liebamn, 2011) on breast cancer and could fit
the requirements for the 12 rules for EGD in cancer. Validations in additional or-
ganisations of care and delivery systems are planned in further validation stages.
RESEARCH POSTER PRESENTATIONS – SESSION II
SELECTED HEALTH CARE TREATMENT STUDIES
MEDICAL DEVICE/DIAGNOSTICS – Clinical Outcomes Studies
PMD1
HISTORICAL TRENDS IN OUTCOMES FOLLOWING AORTIC AND MITRAL HEART
VALVE REPLACEMENT PROCEDURES: A POPULATION-BASED STUDY OF 29,582
MEDICARE PATIENTS FROM 1997 TO 2009
Ong KL1, Patel J1, Watson H2, Helmus M3, Kuehn C4, Ochoa J4
1Exponent, Inc., Philadelphia, PA, USA, 2Exponent, Inc., Menlo Park, CA, USA, 3Exponent, Inc.,
Natick, MA, USA, 4Exponent, Inc., Bellevue, WA, USA
OBJECTIVES: To serve as comparative data for percutaneous valve replacements,
this study sought to characterize the historical outcomes for aortic andmitral valve
replacement surgery in a large, nationally representative population. METHODS:
Patients undergoing aortic ormitral valve replacement were identified from the 5%
national Medicare data (1997-2009) using ICD-9-CM codes 35.21 to 35.24. The sub-
sequent rates of mortality, mechanical complications, infection, and valve re-im-
plantation/reoperation, and infective endocarditis were evaluated. Hospitalization
charges and reimbursements (in Jan 2011 dollars) for the index procedurewere also
assessed. RESULTS: The patient cohort included 12,202 aortic bioprosthesis, 9,757
aortic mechanical valves, 3,222 mitral bioprosthesis, and 4,401 mitral mechanical
valves. The ten-year Kaplan-Meier mortality, mechanical complication, infection,
re-implantation/reoperation, and infective endocarditis rates for aortic biopros-
thesis were 64.4%, 4.41%, 4.54%, 1.50%, and 8.34%, respectively, and for aortic me-
chanical valves were 63.9%, 5.23%, 4.71%, 1.84%, and 9.08%, respectively. The cor-
responding ten-year Kaplan-Meier rates formitral bioprosthesiswere 74.8%, 8.02%,
6.29%, 2.81%, and 12.90%, respectively, and for mitral mechanical valves were
64.7%, 7.60%, 6.06%, 2.87%, and 12.24%, respectively. The average hospitalization
reimbursements for procedures involving aortic bioprostheses, aortic mechanical
valves, mitral bioprostheses, and mitral mechanical valves were $54.3k, $54.6k,
$64.1k, and $62.2k, respectively. CONCLUSIONS: The crude risks of mortality and
complications, as well as payer costs, were found to be higher for mitral valve
replacements compared with aortic valve replacements. This study provides base-
line data for evaluating the comparative effectiveness of percutaneous valve re-
placement to “traditional” approaches, especially since the percutaneous ap-
proach may have inherently different levels of performance or expanded
indications.
PMD2
ADMISSION TO CORONARY ANGIOGRAPHIC CATHETERIZATION IN ARMENIA
AT NORK MARASH MEDICAL CENTER: CHARACTERISTICS AND OUTCOMES
Perikhanyan A
Nork Marash Medical Center, Yerevan, Armenia
OBJECTIVES: The importance of avoiding unnecessary diagnostic invasive angiog-
raphy is emphasized based on risks associated with test and costs. At the same
time, early interventions are important to reduce negative outcomes of coronary
artery disease (CAD). Objective of this study was to analyze the characteristics and
outcomes of cases with possible CAD that underwent coronary angiography cath-
eterization (CAG) from December 2006 to February 2007 consecutively in Nork
Marash Medical Center (NMMC). METHODS: This was a retrospective study of
newly admitted cohort. Predefined exclusion criteria were CAG in other clinic, CAG
for other then CAD reasons and non Armenian residency. RESULTS: Only 200 re-
cordswere corresponding to the criteria. Themean age of caseswas 52.9110 years
and 85% were males (RR0.93). The mean age of women was higher (60 vs 50).
Only 10.5% of participants had normal BMI. Current smokers comprised 60 %(
RR1.17), 74% had hypertension (RR1.165), 30.5% hypercholesterolemia (RR2.5)
and 14.5%DiabetesMellitus (RR4.26). In 26(13%) cases catheterization detected no
CAD at all and 13(6.5%) patients had stenosis50%. Most catheterizations were
elective (68%).There were 2 urgent admissions among patients with CAD50%.
Significantly diseased left anterior descending (LAD) proximal was detected most
frequently (52%).Among patients with stenosis50% 24% of cases underwent PCI,
75% CABG, and 5% bridge to CABG procedure. Thirty two people (20%) were not
treated with revascularization: among them 7 (21.9%) with multivessel disease.
15% of patients with indication to revascularization refused to be treated with any
of procedures. CONCLUSIONS: There is gender inequality in CAG utilization, early
cholesterol control should be encouraged by primary care professionals, patient
preferences play significant role in a treatment decision process in Armenia.
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DOES CURRENT PERCEPTION THRESHOLD TEST CAN DIFFERENTIATE
CATEGORIES OF MECHANICAL NECK DISORDER?
Uddin Z, MacDermid JC, Galea V, Gross AR, Pierrynowski M
McMaster University, Hamilton, ON, Canada
OBJECTIVES: To differentiate three types of Mechanical Neck Disorders (MND) by
Current Perception Threshold (CPT). Specific aims were to: 1) Look whether differ-
ences in CPT exist in MND categories, and 2) Estimate the predicted probability of
the neurological symptoms in type-3 of MND. METHODS: The study design was a
laboratory based cross-sectional discriminative analysis. Patients with MND (N 
106) were assessed for CPT into three groups: MND-mixed (N60), MND-2 (N29),
MND-3 (N17). CPT testing was performed in a standard Quantatative Sensory
Testing laboratory. A one-way ANOVA with post hoc was done for compare the
mean CPT score between the groups. An independent sample t-test was done to
compare the mean CPT and estimated effect size between MND-2 and MND-3
group. The discriminative analysis predicted the group membership in one of the
categories. A binary logistic regressionmodel predicted probability of higher CPT in
MND-3, where CPT score counted as the risk factor to having neurological symp-
toms. A Receiver Operating Characteristic (ROC) curve was created from predicted
probability by binary covariate. RESULTS: Mean CPT differed significantly across
the three groups (F 2, 96  6.69, p  0.002), with a significant higher preference
rating in MND-3 (p  0.004). Moderate discriminates and a small to medium effect
size found between theMND-2 andMND-3. Model discrimination (betweenMND-2
and MND-3) showed 86.2% specificity and 64.7% sensitivity, where an area under
the ROC curvewas 0.836 (95% CI 0.716 - 0.956, p 0.000). CONCLUSIONS: CPT test
was capable of differentiate MND categories. CPT might be a potential tool for
evaluating neurological involvement or hypersensitivity in neck pain.
PMD4
QUALITATIVE MOLECULAR TESTS FOR CONFIRMATION OF THE DIAGNOSIS OF
HEPATITIS C IN SEROPOSITIVE PATIENTS: A SYSTEMATIC REVIEW
Oliveira IG, Pereira C, Portela M
Oswaldo Cruz Foundation, Rio de Janeiro, RJ, Brazil
OBJECTIVES: Hepatitis C represents a serious Public Health problem. In approxi-
mately 80%of cases, the disease becomes chronic and the diagnosis can sometimes
be made before the disease becomes severe. In 1993, the Brazilian government
adopted a screening system with serological kits for hepatitis C diagnosis in blood
donors. A positive screening, however, should be confirmed with another type of
test since they do not distinguish active infection from past infection. So, molecu-
lar tests are very important to establish actual viremia and the hepatitis c diagno-
sis. Many guidelines throughout the world recommend the molecular test in vari-
ous settings, including the confirmation of HCV in seropositive people. There are
different qualitative molecular tests available for detecting HCV. The aim of this
studywas to conduct a systematic reviewof the accuracy of these different tests for
confirmation of the diagnosis of HCV in seropositive people. METHODS: We
searched MEDLINE, SCOPUS and the Cochrane Library. QUADAS was the tool used
for quality assessment of the studies.RESULTS:The search resulted in 1222 articles
for evaluation. Only 2 studies were included in the systematic review, according to
the established inclusion and exclusion criteria. Both COBAS AMPLICOR and AM-
PLICOR tests had high sensitivity and specificity in one of the studies. The second
study, presented accuracy data regarding an “in house” PCR test, which presented
overall accuracy of 75%. CONCLUSIONS: Although we identified many articles in
our search, the vast majority addressed analytical sensitivity, therefore not meet-
ing our criteria, especially because they did not present accuracy data according to
an established a gold standard. Furthermore, the 2 studies included did not present
a good methodological quality according to QUADAS. These findings show the
urgent need of studies with appropriate design for extraction of accuracy data of
molecular tests.
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USE AND FINDINGS OF K-RAS IN COLORECTAL CANCER (CRC) TESTING IN
ADMINISTRATIVE AND ELECTRONIC MEDICAL RECORDS (EMR) DATA FROM
2005 THROUGH 2010
Seal B1, Sullivan SD2, Ramsey S3, Kreilick C4, Foltz-boklage S4, Haslip S5, Gilmore J5,
Sarma S6, Asche C7, Valluri S1
1Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, USA, 2University of Washington, Seattle
, WA, USA, 3Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA,
USA, 4Bayer HealthCare, Wayne, NJ, USA, 5Georgia Cancer Specialists, Atlanta, GA, US, Atlanta,
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OBJECTIVES: The use of K-ras testing in clinical decision-making has grown over
the past few years. The objective of this study was to evaluate, in a real world
context, the trends anddiagnostic findings of K-ras testing usingmanaged care and
EMR data. METHODS: The Georgia Cancer Specialists Database EMR (2005-2010)
and administrative data from theMarketScan and IMPACT database(s) was used to
select patients with newly diagnosed colorectal cancer (CRC). We looked for trends
in use of K-ras in relation to timing of chemotherapy administration. The EMR data
provided information on k-ras mutation type. RESULTS: In MarketScan, of the
23,548 patients with a diagnosis of CRC, 1,730 (7.3%) patients had a test ordered for
K-ras between 2005 and 2010. The number of patients receiving K-ras increased
with line of therapy: first line 336 patients (8.2%) of 4098 treated, second line 455
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